MedTrace Logo

A Study to Evaluate the Drug-drug Interaction and Safety Between "BR6001-1" and "BR6001-2"

NCT06165237 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-02-01

No results posted yet for this study

Summary

The purpose of this clinical trial is to evaluate the drug-drug interaction and safety between "BR6001-1" and "BR6001-2" in healthy adult volunteers

Conditions

  • Gastric or Duodenal Ulcer

Interventions

DRUG

BR6001-1

One tablet administered alone, Once a day

DRUG

BR6001-2

One tablet administered alone, Once a day

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-30
Primary Completion
2023-05-09
Completion
2023-05-09

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06165237 on ClinicalTrials.gov